Woodmont Investment Counsel LLC Sells 300 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Share on StockTwits

Woodmont Investment Counsel LLC decreased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,277 shares of the biopharmaceutical company’s stock after selling 300 shares during the period. Woodmont Investment Counsel LLC’s holdings in Bristol-Myers Squibb were worth $874,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. FMR LLC raised its position in shares of Bristol-Myers Squibb by 313.9% in the first quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock valued at $1,949,043,000 after purchasing an additional 30,981,844 shares during the period. Baupost Group LLC MA increased its holdings in Bristol-Myers Squibb by 225.0% during the 2nd quarter. Baupost Group LLC MA now owns 13,000,000 shares of the biopharmaceutical company’s stock worth $589,550,000 after acquiring an additional 9,000,000 shares during the period. Renaissance Technologies LLC grew its stake in Bristol-Myers Squibb by 67.6% in the 2nd quarter. Renaissance Technologies LLC now owns 20,698,607 shares of the biopharmaceutical company’s stock worth $938,682,000 after buying an additional 8,347,432 shares in the last quarter. BlackRock Inc. grew its stake in Bristol-Myers Squibb by 6.7% in the 2nd quarter. BlackRock Inc. now owns 114,798,394 shares of the biopharmaceutical company’s stock worth $5,206,108,000 after buying an additional 7,178,698 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Bristol-Myers Squibb by 75.7% in the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock worth $732,691,000 after buying an additional 6,960,047 shares in the last quarter. 80.16% of the stock is currently owned by institutional investors and hedge funds.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini acquired 11,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was bought at an average price of $44.72 per share, with a total value of $491,920.00. Following the purchase, the director now owns 11,397 shares of the company’s stock, valued at $509,673.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

BMY has been the subject of a number of research reports. UBS Group cut their price target on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating for the company in a research note on Thursday, June 13th. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target for the company in a research note on Wednesday, August 14th. Goldman Sachs Group initiated coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, May 28th. They issued a “buy” rating and a $54.00 price target for the company. JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. Finally, ValuEngine raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Monday, August 26th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus price target of $55.74.

Shares of Bristol-Myers Squibb stock traded up $0.19 during trading on Thursday, reaching $50.05. The company’s stock had a trading volume of 5,456,773 shares, compared to its average volume of 9,039,890. Bristol-Myers Squibb Co has a 52-week low of $42.48 and a 52-week high of $63.69. The company has a market cap of $80.92 billion, a price-to-earnings ratio of 12.57, a PEG ratio of 2.44 and a beta of 0.70. The firm’s 50-day moving average is $47.43 and its two-hundred day moving average is $47.10. The company has a quick ratio of 3.75, a current ratio of 3.88 and a debt-to-equity ratio of 1.51.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The company had revenue of $6.27 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the prior year, the company earned $1.01 EPS. The firm’s revenue was up 10.0% on a year-over-year basis. On average, equities research analysts anticipate that Bristol-Myers Squibb Co will post 4.29 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.28%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: What is the Quick Ratio?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.